Overview

• EssilorLuxottica announced the purchase of Ikerian AG, which operates as RetinAI, to advance its strategy in AI-driven ophthalmic care.
• RetinAI’s Discovery platform holds FDA 510(k) clearance and CE certification and applies machine learning and computer vision to retinal imaging.
• The technology supports monitoring of age-related macular degeneration, diabetic retinopathy and glaucoma to enable earlier diagnosis and targeted interventions.
• Company leaders said AI analytics will convert clinical data into actionable insights for timelier, more accurate diagnoses and more effective disease tracking.
• Coverage situates the deal within a broader push into AI and connected devices, with Italian reports noting recent authorization to raise a Nikon stake and stated smart-glasses production goals.